John C. Hart

Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

Harlan E. Shannon, Kurt Rasmussen, Frank P. Bymaster et al. · Schizophrenia Research · 2000 · 162 citations

Medicine, Neuroscience, Pharmacology +12

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neurochemical Changes

Matthew Fell, Jeffrey M. Witkin, Julie F. Falcone et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 99 citations

Medicine, Neuroscience, Pharmacology +17

Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine.

J. David Leander, Robert L. Zerbe, John C. Hart · Journal of Pharmacology and Experimental Therapeutics · 1985 · 91 citations

Medicine, Pharmacology, Neuropharmacology +14

Muscarinic Receptor Agonists, Like Dopamine Receptor Antagonist Antipsychotics, Inhibit Conditioned Avoidance Response in Rats

Harlan E. Shannon, John C. Hart, Frank P. Bymaster et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 77 citations

Medicine, Behavioral Sciences, Pharmacology +17

Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344

Linda M. Rorick‐Kehn, E.J. Perkins, Karen M. Knitowski et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 67 citations

Medicine, Pharmacokinetics, Pharmacology +11